Art. -Nr.: HY-17353

BIBR 1532

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

BIBR 1532 is a potent, selective and non-competitive telomerase inhibitor with IC₅₀ of 100 nM in a cell-free assay.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

The BIBR 1532 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.

Reinheit: 99.76%
CAS. Nr.: 321674-73-1
Formel: C₂₁H₁₇NO₃
Molecular Weight:331.36

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

BIBR 1532 Chemical Structure

CAS. Nr.: 321674-73-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

BIBR 1532 is a potent, selective and non-competitive telomerase inhibitor with IC₅₀ of 100 nM in a cell-free assay.

IC₅₀ & Target

IC50: 100 nM (telomerase)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.73 μM Compound: BIBR1532	Antiproliferative activity against human A549 cells by CCK8 assay Antiproliferative activity against human A549 cells by CCK8 assay	[PMID: 34922028]
Calu-3	IC₅₀	0.21 μM Compound: BIBR1532	Antiproliferative activity against human Calu-3 cells by CCK8 assay Antiproliferative activity against human Calu-3 cells by CCK8 assay	[PMID: 34922028]
CT26	IC₅₀	42.905 μM Compound: BIBR1532	Antiproliferative activity against mouse CT26 cells assessed as inhibition of cell growth measured after 96 hrs by CCK-8 assay Antiproliferative activity against mouse CT26 cells assessed as inhibition of cell growth measured after 96 hrs by CCK-8 assay	[PMID: 39140071]
GES1	IC₅₀	205.811 μM Compound: BIBR1532	Cytotoxicity against human GES1 cells assessed as inhibition of cell growth measured after 96 hrs by CCK-8 assay Cytotoxicity against human GES1 cells assessed as inhibition of cell growth measured after 96 hrs by CCK-8 assay	[PMID: 39140071]
HeLa	IC₅₀	0.012 μM Compound: BIBR1532	Antiproliferative activity against human HeLa cells by CCK8 assay Antiproliferative activity against human HeLa cells by CCK8 assay	[PMID: 34922028]
HeLa	IC₅₀	0.093 μM Compound: 13, BIBR1532	Inhibition of human telomerase isolated from human HeLa cells nuclear extracts expressed in insect cells assessed as [33P]dCMP incorporation after 30 mins by liquid scintillation counting analysis Inhibition of human telomerase isolated from human HeLa cells nuclear extracts expressed in insect cells assessed as [33P]dCMP incorporation after 30 mins by liquid scintillation counting analysis	[PMID: 24053596]
HeLa	IC₅₀	0.093 μM Compound: 2, BIBR-1532	Inhibition of telomerase in human HeLa cells after 2 hrs by [alpha-32P]dGTP incorporation assay Inhibition of telomerase in human HeLa cells after 2 hrs by [alpha-32P]dGTP incorporation assay	[PMID: 22413845]
HeLa	IC₅₀	3.6 μM Compound: 2, BIBR-1532	Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction by telomeric repeat amplification protocol Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction by telomeric repeat amplification protocol	[PMID: 22413845]
HeLa	IC₅₀	4.6 μM Compound: 2, BIBR-1532	Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol	[PMID: 22413845]
HL-60	IC₅₀	47.824 μM Compound: BIBR1532	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 96 hrs by CCK-8 assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth measured after 96 hrs by CCK-8 assay	[PMID: 39140071]
L02	IC₅₀	80.45 μM Compound: BIBR1532	Cytotoxicity against human L02 cells by CCK8 assay Cytotoxicity against human L02 cells by CCK8 assay	[PMID: 34922028]
MCF7	IC₅₀	0.52 μM Compound: BIBR1532	Antiproliferative activity against human MCF7 cells by CCK8 assay Antiproliferative activity against human MCF7 cells by CCK8 assay	[PMID: 34922028]
MDA-MB-231	IC₅₀	0.17 μM Compound: BIBR1532	Inhibition of telomerase in human MDA-MB-231 cells after 24 hrs by TRAP-PCR-ELISA Inhibition of telomerase in human MDA-MB-231 cells after 24 hrs by TRAP-PCR-ELISA	[PMID: 25965778]
MDA-MB-231	IC₅₀	0.17 μM Compound: BIBR1532	Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay	[PMID: 34922028]
MGC-803	IC₅₀	0.28 μM Compound: BIBR1532	Inhibition of telomerase in human MGC803 cell extracts after 24 hrs by TRAP-PCR-ELISA Inhibition of telomerase in human MGC803 cell extracts after 24 hrs by TRAP-PCR-ELISA	[PMID: 24119869]
MGC-803	IC₅₀	0.28 μM Compound: BIBR1532	Inhibition of telomerase in human MGC803 cells after 24 hrs by TRAP-PCR-ELISA Inhibition of telomerase in human MGC803 cells after 24 hrs by TRAP-PCR-ELISA	[PMID: 25554922]
MGC-803	IC₅₀	0.41 μM Compound: BIBR1532	Inhibition of telomerase in human MGC803 cell extracts after 24 hrs by TRAP-PCR-ELISA Inhibition of telomerase in human MGC803 cell extracts after 24 hrs by TRAP-PCR-ELISA	[PMID: 25812966]
NCI-H1650	IC₅₀	0.52 μM Compound: BIBR1532	Antiproliferative activity against human H1650 cells by CCK8 assay Antiproliferative activity against human H1650 cells by CCK8 assay	[PMID: 34922028]
NCI-H460	IC₅₀	0.39 μM Compound: BIBR1532	Antiproliferative activity against human H460 cells by CCK8 assay Antiproliferative activity against human H460 cells by CCK8 assay	[PMID: 34922028]

In Vitro

BIBR 1532 non-competitively inhibits telomerase activity^[1]. BIBR 1532 inhibits the proliferation of JVM13 leukemia cells with an IC₅₀ of 52 μM, and similar effect also occurs in other leukemia cell lines such as Nalm-1, HL-60, and Jurkat. BIBR 1532 exerts antiproliferative effect on acute myeloid leukemia (AML) with IC₅₀ of 56 μM with no effect on the proliferative capacity of normal hematopoietic progenitor cells^[2]. BIBR 1532 (2.5 μM) reduces colony-forming ability, induces telomere length shortening and causes chemotherapeutic sensitization via inhibiting telomerase activity in MCF-7/WT and melphalan-resistant MCF-7/MlnR cell lines^[3]. BIBR 1532 is cytotoxic in a dose-dependent manner in T-cell prolymphocytic leukemia (T-PLL)^[4]. BIBR 1532 in combination with carboplatin (a chemotherapeutic agent) eliminates ovarian cancer spheroid-forming cells in ES2, SKOV3, and TOV112D cell lines^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 321674-73-1
Appearance Solid
Molecular Weight 331.36
Formel C₂₁H₁₇NO₃
Color White to light yellow
SMILES

O=C(O)C1=CC=CC=C1NC(/C=C(C2=CC=C3C=CC=CC3=C2)\C)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All Cell Proliferation/Viability AssayCell Imaging/Staining

Sort by:

Journal Impact Factor

Int J Oncol

Establishment and characteristics of GWH04, a new primary human glioblastoma cell line. [Abstract]

2022 Nov;61(5):139. PMID: 36169178

BIBR 1532 purchased from MedChemExpress. Usage Cited in: Int J Oncol. 2022 Nov;61(5):139. [Abstract]

BIBR 1532 (0.1, 1, 5, 10, 20, 40, 80, 160 and 320 µM; 5 days) inhibited cell proliferation in a dose-dependent manner in GWH04, U87 and GL15 cells.
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
J Cell Physiol

Telomere Attrition-Induced Senescence in Human Pluripotent Stem Cell-Derived Astrocytes: Distinct Cellular and Functional Characteristics. [Abstract]

2025 Dec;240(12):e70118. PMID: 41340457

BIBR 1532 purchased from MedChemExpress. Usage Cited in: J Cell Physiol. 2025 Dec;240(12):e70118. [Abstract]

Representative immunofluorescence images of NPCs stained with NESTIN and SOX1 treated with various concentration of BIBR 1532 (BIBR; 0, 10 , 20 , 40 μM; 10 days).

BIBR 1532 purchased from MedChemExpress. Usage Cited in: J Cell Physiol. 2025 Dec;240(12):e70118. [Abstract]

A growth curve of NPCs differentiating from hPSCs, treated with BIBR 1532 (BIBR) at concentration of 0, 10, and 20μM. Cell viability was monitored from the initiation of differentiation (day 0) to day 14.

BIBR 1532 purchased from MedChemExpress. Usage Cited in: J Cell Physiol. 2025 Dec;240(12):e70118. [Abstract]

BIBR 1532 (BIBR; 10 μM; 16 days) did not affect astrocyte differentiation efficiency. In boththe vehicle‐treated control and BIBR‐treated groups, over 90% cell were positive for all tested markers, with no statistically significantdifference between the groups

BIBR 1532 purchased from MedChemExpress. Usage Cited in: J Cell Physiol. 2025 Dec;240(12):e70118. [Abstract]

BIBR 1532 (BIBR; 10 μM; 16 days) had significantlylarge and flattened cell bodies, with highly branched and elongatedprocesses and often multiple nuclei, a phenom-enon referred to as multinucleation.

BIBR 1532 purchased from MedChemExpress. Usage Cited in: J Cell Physiol. 2025 Dec;240(12):e70118. [Abstract]

BIBR 1532 (BIBR; 10 μM; 16 days) showed an increased proportion ofsenescence‐associated β‐galactosidase‐positive cells compared to the vehicle‐treated astrocyte culture.

BIBR 1532 purchased from MedChemExpress. Usage Cited in: J Cell Physiol. 2025 Dec;240(12):e70118. [Abstract]

BIBR 1532 (BIBR; 10 μM; 16 days) revealed significantly more BODIPY‐positive cells. Representative images of LDs (BODIPY 493/503, green) in astrocytes, withcytoplasm defined by Phalloidin‐labeled actin filaments (red).
PLoS One

The mechanism of NF-κB-TERT feedback regulation of granulosa cell apoptosis in PCOS rats. [Abstract]

2024 Oct 25;19(10):e0312115. PMID: 39453929
Research Square Preprint

2025 Jan 05.
bioRxiv

2024 August 07.
Research Square Preprint

2021 Apr.
Patent

US20180263995A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (301.79 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0179 mL

15.0893 mL

30.1787 mL

5 mM

0.6036 mL

3.0179 mL

6.0357 mL

10 mM

0.3018 mL

1.5089 mL

3.0179 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[1]

For the direct telomerase assay with the endogenous telomerase, 10 μL of telomerase-enriched extract is mixed with different concentrations of BIBR1532 in a final volume of 20 μL. After 15-minute preincubation on ice, 20 μL of the reaction mixture is added, and the reaction is initiated by transferring the tubes to 37°C. The final concentrations in the reaction mixture are 25 mM Tris-Cl (pH 8.3), 1 mM MgCl₂, 1 mM EGTA, 1 mM dATP, 1 mM dTTP, 6.3 μM cold dGTP, 15 μCi [α-³²P]dGTP (3000 Ci/mmol; NEN), 1.25 mM spermidine, 10 units of RNasin, 5 mM 2-mercaptoethanol, and 2.5 μM TS-primer (5'-AATCCGTCGAGCAGAGTT). For the recombinant enzyme, 1-7 μL of affinity-purified telomerase (containing less than 0.025 μM hTERT) are assayed in a final volume of 40 μL containing 50 mM Tris acetate (pH 8.5), 50 mM KCl, 1 mM MgCl₂, 1 mM spermidine, 5 mM 2-mercaptoethanol, 1 mM dATP, 1 mM dTTP, 2.5 μM dGTP, 15 μCi of [α-³²P]dGTP (3000 Ci/mmol) and 2.5 μM (TTAGGG)3. The reaction is initiated by incubation at 37°C for 2 hours and stopped by addition of 50 μL of RNase mix (0.1 mg/mL RNaseA-100 u/mL RNaseT1 in 10 mM Tris-Cl (pH 8.3) and 20 mm EDTA) and incubation for 20 min at 37°C. Samples are deproteinated by adding 50 μL of 0.3 mg/m proteinase K in 10 mM Tris-Cl (pH 8.3) and 0.5% w/v SDS, for a 30-minute incubation at 37°C. DNA is recovered by phenol extraction and ethanol precipitation, and the extension products are analyzed on an 8% (endogenous telomerase) or 12% (recombinant telomerase) polyacrylamide-urea gel. Dried gels are exposed to a Kodak phosphorimager screen, and the results are analyzed.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

Cells are plated as triplicates in complete RPMI 1640 medium with various concentrations of BIBR1532. After 24 to 72 hours, water-soluble tetrazolium (WST-1) is added, which is transformed into formazan by mitochondrial reductase systems. The increase in the number of viable cells results in an increase of activity of mitochondrial dehydrogenases, leading to an increase of formazan dye formed, which is quantified by ELISA reader after 2, 3, and 4 hours of incubation.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Pascolo E, et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem. 2002 May 3;277(18):15566-72. [Content Brief]

[2]. El-Daly H, et al. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood. 2005 Feb 15;105(4):1742-9. [Content Brief]

[3]. Ward RJ, et al. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol. 2005 Sep;68(3):779-86. [Content Brief]

[4]. A Röth, et al. Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia. Leukemia. 2007 Dec;21(12):2456-62. [Content Brief]

[5]. Meng E, et al. Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells. Gynecol Oncol. 2012 Mar;124(3):598-605. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0179 mL	15.0893 mL	30.1787 mL	75.4466 mL
	5 mM	0.6036 mL	3.0179 mL	6.0357 mL	15.0893 mL
	10 mM	0.3018 mL	1.5089 mL	3.0179 mL	7.5447 mL
	15 mM	0.2012 mL	1.0060 mL	2.0119 mL	5.0298 mL
	20 mM	0.1509 mL	0.7545 mL	1.5089 mL	3.7723 mL
	25 mM	0.1207 mL	0.6036 mL	1.2071 mL	3.0179 mL
	30 mM	0.1006 mL	0.5030 mL	1.0060 mL	2.5149 mL
	40 mM	0.0754 mL	0.3772 mL	0.7545 mL	1.8862 mL
	50 mM	0.0604 mL	0.3018 mL	0.6036 mL	1.5089 mL
	60 mM	0.0503 mL	0.2515 mL	0.5030 mL	1.2574 mL
	80 mM	0.0377 mL	0.1886 mL	0.3772 mL	0.9431 mL
	100 mM	0.0302 mL	0.1509 mL	0.3018 mL	0.7545 mL

Keywords

BIBR 1532

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BIBR 1532

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Anti-Blood Cancer Compound Library

Targeted Diversity Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) BIBR 1532

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BIBR 1532

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Anti-Blood Cancer Compound Library

Targeted Diversity Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) BIBR 1532

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BIBR 1532 Related Classifications

HY-17353 Related Classifications